Stockreport

NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing [Yahoo! Finance]

NRX Pharmaceuticals, Inc.  (NRXP) 
PDF Potential revenue in 2025 NDA for NRX-100 (IV ketamine) in suicidal depression in advanced preparation for submission in 2024; based on four positive trials and Fast T [Read more]